Cellules souche et Dérivés

CK2α-IN-1 is a selective non-ATP-competitive CK2α inhibitor with an IC50 of 7.0 µM and a Ki of 1.6 µM.CK2α-IN-1 exhibits potential anticancer activity and can

Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.

Garetosmab (REGN 2477), a human IgG4 monoclonal antibody, inhibits activin A for potential cancer treatment and FOP study.

MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.

BMS-986148 is a CHO-expressed humanized antibody-drug coupling targeting mesothelin-expressing cells for cytotoxic load delivery.

LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).

LH846 is a selective inhibitor of CK1δ (IC50 values are 290 nM, 1.3 uM and 2.5 uM for CK1δ, ε and α); exhibits no inhibitory activity at CK2.

JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.

AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).

JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].

Laduviglusib trihydrochloride, a GSK-3α/β inhibitor (IC50: 10/6.7 nM), activates Wnt/β-catenin signaling and induces autophagy.

5-bromoindole is a potential inhibitor of glycogen synthase kinase 3 (GSK-3)and an important pharmaceutical chemical intermediate

WZ-2-033 is a potent STAT3 inhibitor. It inhibits proliferation, colony survival, migration, and invasion of MDA-MB-231, HCC70, and MDA-MB231-4175 cells, with IC50 values of 0.7, 1.3, and 1.3 μM respectively.

GSK3-IN-1 is a GSK3B-glycogen synthase kinase-3 beta inhibitor.

NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3 that enhances the aggregation of misfolded prion proteins NT219 Effects.

inS3-54-A26 is an inhibitor of the DNA-binding domain of STAT3. inS3-54-A26 suppresses tumor growth, metastasis and the gene expression of STAT3.

ROCK-IN-7 (compound 9) serves as a ROCK kinase inhibitor and is utilized in the investigation of ocular conditions, including glaucoma and retinal diseases [1].

HLY78, a Wnt/β-catenin activator, enhances Axin-LRP6 binding by targeting Axin's DIX domain.

DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.

RO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.

Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.

Bikinin (Abrasin), a potent inhibitor of plant GSK-3/Shaggy-like kinase, activates BR signaling downstream of the BR receptor.

γ-Secretase modulator 13 is a γ-secretase modulator (GSMs) that can be used to study Alzheimer's disease and tumors.

Kartogenin (KGN) is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes.

2H-1-Benzopyran-3-carboxamide, N-[4-(4-ethyl-1-piperazinyl)phenyl]-2-oxo- is a compound that is potential for the treatment of tumours.

PF-670462 is a potent (IC50 = 7.7 ± 2.2 nM) and selective (>30-fold with respect to 42 additional kinases) inhibitor of CK1ε in isolated enzyme preparations.

Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.

F7H is an FZD7 antagonist, a potent ligand for the FZD7 transmembrane domain (TMD), with potential antitumor and bacteriostatic activities.

STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and

Naftifine HCl: synthetic antifungal; inhibits squalene epoxidase, disrupting fungal cell sterol synthesis.

MNK8 is a potent STAT3 inhibitor, impairs DNA binding, and inhibits liver cancer cell growth.

JW 67 is an inhibitor of canonical Wnt pathway signaling.

JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).

Jervine inhibits Smoothened, blocking Hedgehog signaling and GLI1 transcription activation.

S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.

TEAD-IN-6 (Example 11-1) is a TEAD modulator that inhibits the YAP1/TAZ-TEAD interaction, and has applications in cancer research [1].

GNF-6231 is a potent, selective, and orally bioavailable Porcupine inhibitor that blocks Wnt signaling.

BRD0705: potent, selective GSK3α inhibitor, oral, IC50: 66 nM, 8x more selective than GSK3β.

Teplinovivint is a potent inhibitor of the Wnt/β-catenin signaling pathway, demonstrating anti-inflammatory properties with potential utility in tendinopathy

Fosciclopirox (CPX-POM), the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire

This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Mouse TNNI3/cTn-I. Samples (or Standards) are added to the micro ELISA plate wells and combined with the specific antibody and biotinylated detection antibody specific for Mouse TNNI3/cTn-I. Then Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Mouse TNNI3/cTn-I, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm. The OD value is proportional to the concentration of Mouse TNNI3/cTn-I. You can calculate the concentration of Mouse TNNI3/cTn-I in the samples by comparing the OD of the samples to the standard curve.

CKI-7 is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor.

Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.

MLN8054 is a potent and selective Aurora A kinase inhibitor with an IC50 of 4 nM.

AZD8542 is an antagonist of Smoothened (SMO) with potential as an oncology therapeutic.

AS-252424 is a potent and selective inhibitor of PI3Kγ with IC50 of 33 nM; >10 fold selectivity for PI3Kγ versus PI3Kα.

NIBR-LTSi is a selective LATS kinase inhibitor that also activates YAP signaling, promotes tissue stem cell expansion and tissue regeneration in vitro/vivo.

(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.

CK2-IN-4 is a protein kinase (CK2) inhibitor with an IC50 value of 8.6 µM.

CIA-1 inhibits the nuclear receptor COUP-TFII, with IC50s ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines.CIA-1 inhibits the growth of a variety of